Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

European Journal of Nuclear Medicine and Molecular Imaging(2020)10.1007/s00259-020-05097-ySource: DataRank Database

Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma is a research paper published in European Journal of Nuclear Medicine and Molecular Imaging (2020). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 1.15)OA: greenTopics (40)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Alexander Zheleznyak ORCID,Matt Mixdorf,Julie O’Neal ORCID,Julie Ritchey,Michael P. Rettig ORCID

Live enrichment

PubMed:33179150 PMC:PMC8110592 OpenAlex:https://openalex.org/W3106048667

National Cancer Institute

Grant: U54 CA199092

National Cancer Institute

Grant: R01 CA248493

National Institutes of Health

Grant: R01 EB021048

NCI NIH HHS

Grant: R50 CA211466

NIH HHS

Grant: S10 OD020129

NCI NIH HHS

Grant: P30 CA091842

NIGMS NIH HHS

Grant: P41 GM103422

NIH HHS

Grant: S10 OD025264

NIH HHS

Grant: S10 OD027042

National Institutes of Health

Grant: 1S10OD025264-01

Multispectral Optoacoustic Tomography (MSOT) System

National Institutes of Health

Grant: 1S10OD027042-01

IVIS Spectrum CT Preclinical In Vivo Imaging System

National Institutes of Health

Grant: 5R01CA248493-05

Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis

National Institutes of Health

Grant: 5R01EB021048-04

NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPY OF TUMORS

National Institutes of Health

Grant: 1S10OD020129-01

FLUORESCENCE MOLECULAR TOMOGRAPHY SYSTEM

National Institutes of Health

Grant: 5P41GM103422-37

A Resource for Biomedical Mass Spectrometry

National Institutes of Health

Grant: 1U54CA199092-01

Developmental Project

FWCI

1.15

Citation Percentile

0.8%

Citation Trend

2021

2022

2024

2025

2026

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8110592

publisherhttps://link.springer.com/content/pdf/10.1007/s00259-020-05097-y.pdf

publisherhttps://link.springer.com/article/10.1007/s00259-020-05097-y/fulltext.html

journalhttps://doi.org/10.1007/s00259-020-05097-y

Fields of Study

Multiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisRadiopharmaceutical Chemistry and Applications0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansMultiple MyelomaTissue DistributionZirconiumMice, SCIDCell Line, TumorPositron-Emission TomographyMiceAntibodies, Monoclonal, Humanized

Keywords

BiodistributionIn vivoCancer researchMonoclonal antibodyEx vivoMedicineMultiple myelomaChemistryNuclear medicineAntibodyImmunologyBiologyPET imagingCs1 Antigen[89Zr]dfo-elotuzumabMice, SCIDAntibodies, Monoclonal, HumanizedMiceCell Line, TumorPositron-Emission TomographyAnimalsHumansTissue DistributionZirconium

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET

10.6084/m9.figshare.16703044.v1figshare

Additional file 1 of In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET

10.6084/m9.figshare.16703044figshare